GlaxoSmithKline

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, GlaxoSmithKline sits in the top decile of US sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count).

1,345 total trials 50 currently recruiting 1130 completed early-phase tilt top decile by trial count

GlaxoSmithKline: 1,345 sponsored US clinical trials, 50 recruiting.

GlaxoSmithKline sponsors 1,345 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 1,130 completed. 486 of these trials are in Phase 3-4 (later-stage) and 791 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 30 trials.

Top-decile sponsor footprint

GlaxoSmithKline ranks in the top decile of sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 66/100

1,130 of 1,249 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,345 total, page 22 of 27

COMPLETED Phase 3

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

NCT00382993

COMPLETED Phase 3

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

NCT00424255

TERMINATED Phase 4

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

NCT00346749

COMPLETED Phase 2

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

NCT00398645

COMPLETED Phase 1

A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

NCT00405080

COMPLETED Phase 2

Treatment Of Patients With Social Anxiety Disorder

NCT00397722

COMPLETED Phase 3

Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children

NCT00383123

COMPLETED Phase 1

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

NCT00404274

COMPLETED Phase 2

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

NCT00430781

COMPLETED Phase 3

Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

NCT00402363

COMPLETED Phase 1

A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers

NCT00501683

COMPLETED Phase 2

Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

NCT00387127

COMPLETED Phase 3

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

NCT00383162

COMPLETED Phase 2

Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults

NCT00398125

COMPLETED

To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug

NCT00436228

COMPLETED Phase 2

Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer

NCT00367679

COMPLETED Phase 1

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

NCT00376896

COMPLETED Phase 3

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

NCT00370331

COMPLETED Phase 1

A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Smokers.

NCT00429728

COMPLETED Phase 3

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

NCT00385255

COMPLETED Phase 1

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

NCT00404378

COMPLETED Phase 1

Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers

NCT00394030

COMPLETED Phase 2

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

NCT00421707

COMPLETED Phase 4

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

NCT00377611

COMPLETED Phase 4

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

NCT00400608

COMPLETED Phase 4

12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome

NCT00373542

COMPLETED Phase 1

A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.

NCT00386347

COMPLETED Phase 2

28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men

NCT00398580

COMPLETED Phase 1

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride

NCT00400335

COMPLETED Phase 1

Absorption, Distribution, Metabolism And Excretion Study For GSK221149A

NCT00457925

COMPLETED Phase 1

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

NCT00388596

COMPLETED Phase 1

A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

NCT00401479

COMPLETED Phase 4

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

NCT00386100

COMPLETED Phase 1

A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

NCT00404963

TERMINATED Phase 1

Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults

NCT00439959

TERMINATED Phase 1

Odiparcil QT Definitive Study

NCT00437242

COMPLETED Phase 1

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

NCT00442871

COMPLETED Phase 3

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824

COMPLETED Phase 2

Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

NCT00377585

COMPLETED Phase 1

A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients

NCT00363194

COMPLETED Phase 3

TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine

NCT00385008

COMPLETED Phase 1

Topotecan Pharmacokinetic Characterization Study

NCT00361803

COMPLETED Phase 2

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

NCT00359619

COMPLETED Phase 2

Intravenous Mepolizumab In Children With Eosinophilic Esophagitis

NCT00358449

COMPLETED Phase 1

Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment

NCT00358813

COMPLETED Phase 3

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579

COMPLETED Phase 3

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

NCT00380211

COMPLETED Phase 3

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

NCT00387881

COMPLETED Phase 3

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

NCT00359983

TERMINATED Phase 2

A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

NCT00437164

← Previous Page 22 of 27 Next →

Phase Distribution

PhaseTrial count
Phase 1 440
Phase 2 351
Phase 3 377
Phase 4 109

What is open in the GlaxoSmithKline pipeline

50 recruiting of 1,345 indexed (4% open); 1,130 completed (84%).

Phase mix: 486 late (III/IV) vs 791 early (I/II) (early-phase heavy).

Top condition: Pulmonary Disease, Chronic Obstructive (30 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

GlaxoSmithKline: open-pipeline peers nationwide

Peers matched on 1,345 registered trials and 4% open enrollment, not the therapeutic-area sidebar.

GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share GlaxoSmithKlineEli Lilly and CompanyUniversity of MichiganNovartis PharmaceuticalsAstraZenecaStryker OrthopaedicsUS Oncology ResearchOtsuka Pharmaceutical Development & CommercializationTeva Branded Pharmaceutical Products R&D
GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,345 trials (± recruiting share)

Sponsors near 4% open enrollment (± trial volume)

What to do with this GlaxoSmithKline page

1,345 registered trials is a research-attention snapshot, not an endorsement of GlaxoSmithKline or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GlaxoSmithKline pipeline card: 1,345 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.